// App-Quantinova.ai

10 : KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—New data after an additional 1 year of follow-up.

Researchers

Presenter

  • Leonard Joseph Appleman

Principal Investigators

  • William R. Berry

  • Margitta Retz

  • Loic Mourey

  • Josep M. Piulats

  • Emanuela Romano

  • Gwenaelle Gravis

  • Howard Gurney

  • Johann S. De Bono

  • Martin Boegemann

  • Urban Emmenegger

  • Anthony M. Joshua

  • Christophe Massard

  • Srikala S. Sridhar

  • Henry Jacob Conter

  • Xin Tong Li

  • Charles Schloss

  • Christian Heinrich Poehlein

  • Evan Y. Yu

Medical Centers

  • University of Pittsburgh Medical Center, Pittsburgh, PA

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Duke Cancer Center Cary, Cary, NC

  • Rechts der Isar University Hospital, Technical University of Munich, Munich, Germany

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • Catalan Institute of Oncology, Badalona, Spain

  • INSERM U932, Center for Cancer Immunotherapy, Institut Curie, Paris, France

  • Institut Paoli-Calmettes, Marseille, France

  • Macquarie University Hospital, Sydney, Australia

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • University Hospital of Muenster, Muenster, Germany

  • Sunnybrook Research Institute, Toronto, ON, Canada

  • The Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia

  • Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University of Western Ontario, London, ON, Canada

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Washington, Seattle, WA

Locations

  • United States

  • Canada

  • Germany

  • France

  • Spain

  • Australia

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Musculoskeletal

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Pembrolizumab

  • Enzalutamide

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • I

Study Id's

  • NCT02861573

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved